SigNature® T Traceability System to be Installed in Egypt to Tag Two Cotton Varietals
Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based manufacturing for product authenticity and traceability solutions, announced today it received an order for the implementation of its SigNature® T cotton traceability system in Egypt to indelibly mark two varietals of high-value Egyptian cotton, widely acknowledged to be among the finest in the world. The molecular tag and delivery system have been shipped and cotton tagging is expected to commence within the month. The system, already installed in eight cotton gins worldwide, includes the use of unique SigNature T molecular tags, internet-based data collection linking evidence of tagging process quality to each bale ID, and bar code scanning of tagged packaged bales for inventory management and tracking. The cotton fiber will be managed with strict protocols throughout the supply chain to ensure purity and traceability.
“With receipt of this order for Egyptian cotton supply chain tagging and testing, we are moving to replicate our success in securing U.S. cotton through its supply chain. Given the uncertainty surrounding the provenance of Egyptian cotton in the marketplace and growing calls for increased transparency and traceability by consumers, brands and industry advocates, the implementation of our SigNature T cotton traceability system endeavors to ensure that the value of Egyptian cotton can be substantiated throughout its supply chain,” said Dr. James A. Hayward, president and CEO of Applied DNA.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of net losses, limited financial resources, limited market acceptance, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on February 7, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005237/en/
investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, email@example.com
media contact: Meryl Rader, 781-639-4924, firstname.lastname@example.org
program contact: MeiLin Wan, Vice President of Sales, 631-240-8849, email@example.com